Oral Calcium Supplements Associate With Serial Coronary Calcification: Insights From Intravascular Ultrasound.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
01 2021
Historique:
received: 31 12 2019
revised: 04 06 2020
accepted: 26 06 2020
pubmed: 24 8 2020
medline: 22 7 2021
entrez: 24 8 2020
Statut: ppublish

Résumé

This study sought to evaluate and assess the extent of serial coronary artery calcification in response to oral calcium supplementation. Oral calcium supplements are frequently used despite their cardiovascular safety remaining controversial. Their effects on serial coronary calcification are not well established. In a post hoc patient-level analysis of 9 prospective randomized trials using serial coronary intravascular ultrasound, changes in serial percentage of atheroma volume (PAV) and calcium indices (CaI) were compared in matched segments of patients coronary artery disease who were receiving concomitant calcium supplements (n = 447) and in those who did not receive supplements (n = 4,700) during an 18- to 24-month trial period. Patients (mean age 58 ± 9 years; 73% were men; 43% received concomitant high-intensity statins) demonstrated overall annualized changes in PAV and CaI with a mean of -0.02 ± 1.9% (p = 0.44) and a median of 0.02 (interquartile range: 0.00 to 0.06) (p < 0.001) from baseline, respectively. Following propensity-weighted mixed modeling adjusting for treatment and a range of demographic, clinical, ultrasonic, and laboratory parameters (including but not limited to sex, race, baseline, and annualized change in PAV, baseline CaI, concomitant high-intensity statins, diabetes mellitus, renal function), there were no significant between-group differences in annualized changes in PAV (least-squares mean: 0.09; 95% confidence interval [CI]: -0.20 to 0.37 vs. 0.01; 95% CI: -0.27 to 0.29; p = 0.092) according to calcium supplement intake. Per a multivariable logistic regression model accounting for the range of covariates described, calcium supplementation independently associated with an increase in annualized CaI (odds ratio: 1.15; 95% CI: 1.05 to 1.26; p = 0.004). Oral calcium supplementation may increase calcium deposition in the coronary vasculature independent of changes in atheroma volume. The impact of these changes on plaque stability and cardiovascular outcomes requires further investigation.

Sections du résumé

OBJECTIVES
This study sought to evaluate and assess the extent of serial coronary artery calcification in response to oral calcium supplementation.
BACKGROUND
Oral calcium supplements are frequently used despite their cardiovascular safety remaining controversial. Their effects on serial coronary calcification are not well established.
METHODS
In a post hoc patient-level analysis of 9 prospective randomized trials using serial coronary intravascular ultrasound, changes in serial percentage of atheroma volume (PAV) and calcium indices (CaI) were compared in matched segments of patients coronary artery disease who were receiving concomitant calcium supplements (n = 447) and in those who did not receive supplements (n = 4,700) during an 18- to 24-month trial period.
RESULTS
Patients (mean age 58 ± 9 years; 73% were men; 43% received concomitant high-intensity statins) demonstrated overall annualized changes in PAV and CaI with a mean of -0.02 ± 1.9% (p = 0.44) and a median of 0.02 (interquartile range: 0.00 to 0.06) (p < 0.001) from baseline, respectively. Following propensity-weighted mixed modeling adjusting for treatment and a range of demographic, clinical, ultrasonic, and laboratory parameters (including but not limited to sex, race, baseline, and annualized change in PAV, baseline CaI, concomitant high-intensity statins, diabetes mellitus, renal function), there were no significant between-group differences in annualized changes in PAV (least-squares mean: 0.09; 95% confidence interval [CI]: -0.20 to 0.37 vs. 0.01; 95% CI: -0.27 to 0.29; p = 0.092) according to calcium supplement intake. Per a multivariable logistic regression model accounting for the range of covariates described, calcium supplementation independently associated with an increase in annualized CaI (odds ratio: 1.15; 95% CI: 1.05 to 1.26; p = 0.004).
CONCLUSIONS
Oral calcium supplementation may increase calcium deposition in the coronary vasculature independent of changes in atheroma volume. The impact of these changes on plaque stability and cardiovascular outcomes requires further investigation.

Identifiants

pubmed: 32828785
pii: S1936-878X(20)30606-9
doi: 10.1016/j.jcmg.2020.06.030
pii:
doi:

Substances chimiques

Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-268

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Najdat Bazarbashi (N)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

Samir R Kapadia (SR)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Stephen J Nicholls (SJ)

Department of Cardiology, MonashHeart, Monash University, Melbourne, Victoria, Australia.

Julie Carlo (J)

Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Ohio.

Mohamed M Gad (MM)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Manpreet Kaur (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Antonette Karrthik (A)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Yasser M Sammour (YM)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Mohamed Diab (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Keerat Rai Ahuja (KR)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

E Murat Tuzcu (EM)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Steven E Nissen (SE)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Ohio.

Rishi Puri (R)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Ohio. Electronic address: purir@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH